Contribution of BRCA1 and BRCA2 Germ Line Mutations to Triple Negative Breast Cancer Patients
- سال انتشار: 1394
- محل انتشار: اولین سمپوزیوم بین المللی سرطان نسترن
- کد COI اختصاصی: NASTARANCANSER01_007
- زبان مقاله: انگلیسی
- تعداد مشاهده: 693
نویسندگان
Shaukat Khanum Memorial Cancer Hospital and Research Centre (SKMCH & RC), Lahore, Pakistan- German Cancer Research Center (DKFZ), Molecular Genetics of Breast Cancer, Heidelberg, Germany
Shaukat Khanum Memorial Cancer Hospital and Research Centre (SKMCH & RC), Lahore, Pakistan
Shaukat Khanum Memorial Cancer Hospital and Research Centre (SKMCH & RC), Lahore, Pakistan
Shaukat Khanum Memorial Cancer Hospital and Research Centre (SKMCH & RC), Lahore, Pakistan
چکیده
Objectives: Women harboring BRCA1/2 mutations have high lifetime risks of developing breast and ovarian cancer. Current criteria for BRCA1/2 testing to identify individuals at-risk rely predominantly on family history of breast/ovarian cancer and early age of disease onset. Here we investigated if the triple-negative breast cancer (TNBC) phenotype is pertinent in identifying candidates for BRCA1/2 testing in Pakistan. Methods: Five hundred and twenty-three breast cancer patients including 237 diagnosed with early-onset disease (< 30 years of age) and 286 with a positive family history of breast/ovarian cancer were enrolled at the SKMCH & RC from June 2001 to February 2014. All patients underwent comprehensive BRCA1/2 testing for small-range mutations and large genomic rearrangements. Results: Of the breast cancer patients, 36.7% (192/523) presented with TNBC. BRCA1/2 mutation screening revealed 73 mutations in this group: 71 (97.3%) in BRCA1 and two (2.7%) in BRCA2. The prevalence of BRCA1 mutations was 37.0% (71/192), which was significantly higher compared to that of non-TNBC cases (10.3% (34/331)) (P < 0.0001). In the subgroups of early-onset and familial breast/ovarian cancer patients BRCA1 mutations were also more common in TNBC than non-TNBC patients (14.5% (13/90) vs. 5.5% (8/147), P=0.03) and (56.9% (58/102) vs.14.1% (26/184), P < 0.0001), respectively. TNBC patients harboring BRCA1 mutations (n=71) were diagnosed at later age than non-carriers (n=119) (p=0.002). Conclusion: The high prevalence of BRCA1 mutations in Pakistani TNBC patients with early- onset disease regardless of a family history of breast/ovarian cancer and the predominance of BRCA1 mutations suggest TNBC status to be included as a criterion for BRCA1 testing in Pakistan.کلیدواژه ها
مقالات مرتبط جدید
اطلاعات بیشتر در مورد COI
COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.
کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.